DK161090B - Phenylpiperazinphosphonater samt farmaceutisk sammensaetning indeholdende disse - Google Patents
Phenylpiperazinphosphonater samt farmaceutisk sammensaetning indeholdende disse Download PDFInfo
- Publication number
- DK161090B DK161090B DK355686A DK355686A DK161090B DK 161090 B DK161090 B DK 161090B DK 355686 A DK355686 A DK 355686A DK 355686 A DK355686 A DK 355686A DK 161090 B DK161090 B DK 161090B
- Authority
- DK
- Denmark
- Prior art keywords
- methyl
- compounds
- phenyl
- calcium
- phosphonate
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title description 3
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 description 41
- 239000000460 chlorine Substances 0.000 description 24
- -1 R is H Chemical group 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 10
- 229910001424 calcium ion Inorganic materials 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 206010020772 Hypertension Diseases 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000008485 antagonism Effects 0.000 description 6
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 229940127291 Calcium channel antagonist Drugs 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 230000003276 anti-hypertensive effect Effects 0.000 description 4
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000002464 muscle smooth vascular Anatomy 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 150000003839 salts Chemical group 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- RDVLKFWQJDSWBB-UHFFFAOYSA-N Cl.OP(O)=O Chemical compound Cl.OP(O)=O RDVLKFWQJDSWBB-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002327 cardiovascular agent Substances 0.000 description 2
- 229940125692 cardiovascular agent Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- VNZLQLYBRIOLFZ-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCNCC1 VNZLQLYBRIOLFZ-UHFFFAOYSA-N 0.000 description 1
- WICKLEOONJPMEQ-UHFFFAOYSA-N 1-(2-methylphenyl)piperazine Chemical compound CC1=CC=CC=C1N1CCNCC1 WICKLEOONJPMEQ-UHFFFAOYSA-N 0.000 description 1
- DMHZDOTYAVHSEH-UHFFFAOYSA-N 1-(chloromethyl)-4-methylbenzene Chemical group CC1=CC=C(CCl)C=C1 DMHZDOTYAVHSEH-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 1
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- QXRURGISOTUXOD-UHFFFAOYSA-N Cl.P(OC(C1=CC=C(C=C1)CN1CCN(CC1)C1=C(C=CC=C1)OC)(CC)CC)(O)=O Chemical compound Cl.P(OC(C1=CC=C(C=C1)CN1CCN(CC1)C1=C(C=CC=C1)OC)(CC)CC)(O)=O QXRURGISOTUXOD-UHFFFAOYSA-N 0.000 description 1
- ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- YKTDVTPAYJCNMP-UHFFFAOYSA-N OP(O)=O.C1CNCCN1C1=CC=CC=C1 Chemical class OP(O)=O.C1CNCCN1C1=CC=CC=C1 YKTDVTPAYJCNMP-UHFFFAOYSA-N 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010043087 Tachyphylaxis Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 229960002925 clonidine hydrochloride Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 1
- 229960003602 guanethidine Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- UJTMLNARSPORHR-UHFFFAOYSA-N oc2h5 Chemical compound C=C=[O+] UJTMLNARSPORHR-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid group Chemical group C(C(=O)O)(=O)O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 150000003008 phosphonic acid esters Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 150000003444 succinic acids Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000025102 vascular smooth muscle contraction Effects 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G11—INFORMATION STORAGE
- G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
- G11B5/00—Recording by magnetisation or demagnetisation of a record carrier; Reproducing by magnetic means; Record carriers therefor
- G11B5/02—Recording, reproducing, or erasing methods; Read, write or erase circuits therefor
- G11B5/09—Digital recording
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
-
- G—PHYSICS
- G11—INFORMATION STORAGE
- G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
- G11B5/00—Recording by magnetisation or demagnetisation of a record carrier; Reproducing by magnetic means; Record carriers therefor
- G11B5/48—Disposition or mounting of heads or head supports relative to record carriers ; arrangements of heads, e.g. for scanning the record carrier to increase the relative speed
- G11B5/58—Disposition or mounting of heads or head supports relative to record carriers ; arrangements of heads, e.g. for scanning the record carrier to increase the relative speed with provision for moving the head for the purpose of maintaining alignment of the head relative to the record carrier during transducing operation, e.g. to compensate for surface irregularities of the latter or for track following
- G11B5/584—Disposition or mounting of heads or head supports relative to record carriers ; arrangements of heads, e.g. for scanning the record carrier to increase the relative speed with provision for moving the head for the purpose of maintaining alignment of the head relative to the record carrier during transducing operation, e.g. to compensate for surface irregularities of the latter or for track following for track following on tapes
- G11B5/588—Disposition or mounting of heads or head supports relative to record carriers ; arrangements of heads, e.g. for scanning the record carrier to increase the relative speed with provision for moving the head for the purpose of maintaining alignment of the head relative to the record carrier during transducing operation, e.g. to compensate for surface irregularities of the latter or for track following for track following on tapes by controlling the position of the rotating heads
- G11B5/592—Disposition or mounting of heads or head supports relative to record carriers ; arrangements of heads, e.g. for scanning the record carrier to increase the relative speed with provision for moving the head for the purpose of maintaining alignment of the head relative to the record carrier during transducing operation, e.g. to compensate for surface irregularities of the latter or for track following for track following on tapes by controlling the position of the rotating heads using bimorph elements supporting the heads
- G11B5/5921—Disposition or mounting of heads or head supports relative to record carriers ; arrangements of heads, e.g. for scanning the record carrier to increase the relative speed with provision for moving the head for the purpose of maintaining alignment of the head relative to the record carrier during transducing operation, e.g. to compensate for surface irregularities of the latter or for track following for track following on tapes by controlling the position of the rotating heads using bimorph elements supporting the heads using auxiliary signals, e.g. pilot signals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
2
DK 161090 B
R—^-A-^-B~COOH
5 hvor A er en binding eller lavere alkylen, B er en binding eller eventuelt umættet lavere alkylen, 10 R er H, alkyl (eller eventuelt substitueret alkyl), aralkyl, aryl, acyl eller phenacyl etc., forudsat at når A er en binding, er R ikke H, methyl, ethyl, hydroxyethyl, benzyl eller phenyl. De ovennævnte forbindelser har strukturelt ingen relation til phosphon-15 syreesterne ifølge opfindelsen. Desuden omtales de ovennævnte carboxylsyreestere som kun værende i besiddelse af lipid-reducerende aktivitet og inhiberende virkning på thrombocytsammenklumpning og har således på grund af deres afvigende kemiske struktur farmakologiske egenska-20 ber, der er forskellige fra dem, de antihypertensive forbindelser ifølge opfindelsen har.
Som anvendt her definerer udtrykkene "alkyl" og "alkoxy" ligekædede eller forgrenede carbon-carbonbin-dinger, hvor antallet af carbonatomer er anført. Repræ-25 sentative alkylmolekyIdele i hver gruppe omfatter methyl, ethyl, propyl, butyl, pentyl, sek.-butyl etc. og de tilsvarende andre isomere former deraf.
Udtrykket "halogen" omfatter brom, chlor og fluor, idet chlor og fluor er særlig foretrukne.
30 Forbindelser ifølge opfindelsen kan også frem stilles som syreadditionssaltformer deraf. Typiske for sådanne "farmaceutisk acceptable syreadditionssalte" er dem, der er afledt af mineral- eller organiske syrer, herunder f.eks. saltsyre, brombrintesyre, iodbrintesyre, 35 svovlsyre, salpetersyre, eddikesyre, oxalsyre, citronsyre, maleinsyre og ravsyre.
DK 161090 B
3
Repræsentative for særligt foretrukne forbindelser ifølge opfindelsen er sådanne, hvor et af symbolerne X, Y og W er methyl eller methoxy, og de øvrige er hydrogen, og A og Z begge er -CH2-, samt de farmaceutisk acceptable 5 svovlsyreadditionssalte deraf.
Ved de mest foretrukne forbindelser ifølge den foreliggende opfindelse er phosphonatester-molekyIdelen i para-stilling på phenylringen, og substituenterne svarende til X, Y eller W er i ortho- eller parastilling på 10 den phenylring, hvortil de er bundet.
Forbindelserne ifølge opfindelsen kan let fremstilles ifølge et af de følgende reaktionsskemaer eller modifikationer deraf, idet der anvendes let tilgængelige udgangsmaterialer, reagenser og gængse synteseprocedurer.
15 20 25 30
O
4
DK 161090 B
i ™ Ό •d LT) •S δ 115 -5¾ cT „ 5 8d sø
Su la P 0=fe _,!! - o I H* C Ψ , . Pi—B Pi λ έ i in —±-Ϊ* / WCN.
0 [n]
10 s KJJ
1 H
0=fe >1 _ T
I & Ό I
P -d K M
B Η. I V-ca i o c > tk .¾ ’El <5.
ΠΙ *p'"b Bγ-Γ*1 ^.v.
g B § 8 15 §>
n Jb Ό Mm I
H 9 il i§ η ^ *" s~ m jg M 8 fe
m rfevi mn I
§ Sefe Ή
20 -Η WN
4-> Λ 1 O
^ !S o « jfl o—fe
« . 0Μ < I
s
Pi i - I Co] fe] *" ro
30 V
& 35
5 DK 161090 B
O JN
LO
ffl
CM
8 CM Oawft
Ol *ri J fe -> O-Λ 0=0 t 9 . n o T x 10 9 0=0. ' 2 ts 15 I H ° lo" H Jv *”} 0=0 Vi cm h rfefe H 3 8 8·.
g y 's
i ® bT
m aT w o S υ to o uj 1 _4 rj I fi 0=(¾
O u o N
20 5 " Ti 5 £ t £ ,ΚΧ « S [01
Pi O Ρί
S I
2 o" CM « in ΠΙΕ dj 25 ^ »
8 J
°4 O
30 i \i 35
DK 161090 B
6
Forbindelserne ifølge opfindelsen kan indgives i sådanne orale doseringsformer som tabletter, kapsler, piller, pulvere, granulat, eliksirer' eller sirupper. På lignende måde kan de også indgives intravasku-5 lært, intraperitonealt, subcutant eller intramuskulært i de gængse former inden for farmacien. I almindelighed foretrækkes oral indgift. En effektiv, men ikke--toksisk mængde forbindelse anvendes til behandling af hypertension eller til at fremme calciumantagonisme etc.
10 med deraf følgende cardiovaskulær bedring. Det doseringsskema, hvori forbindelserne ifølge opfindelsen anvendes, vælges i overensstemmelse med sådanne faktorer, som patientens type, alder, vægt, køn og lægelige tilstand, sværhedsgraden af den tilstand, der skal bedres, indgifts-15 vejen og den særlige forbindelse , der anvendes, eller blandinger deraf. En alment uddannet læge kan let bestemme og foreskrive den effektive mængde lægemiddel, der er nødvendig for at forebygge, behandle eller standse tilstandens fremadskriden. Doseringer af forbindel-20 serne ifølge opfindelsen, når de anvendes med henblik på de anførte cardiovaskulære virkninger, f.eks. anti-hypertensive, ligger i intervallet mellem ca. 0,1 mg/ kg/dag og. ca. 50 mg/kg/dag. De nævnte dosisintervaller på vægtbasis svarer til en samlet dagsdosis til en 25 voksen gennemsnitspatient på mellem ca. 10 mg/dag og 350 mg/dag. Forbindelserne ifølge opfindelsen indgives bedst i en enkelt daglig dosis, eller den samlede dagsdosis kan indgives i ens opdelte doser tre eller fire gange daglig.
30 I de farmaceutiske sammensætninger ifølge opfin delsen vil de ovenfor omtalte aktive stoffer blive indgivet blandet med passende farmaceutiske bærestoffer (her samlet kaldet bærematerialer), der er udvalgt med henblik på den tilsigtede indgiftsform, dvs. orale tablet-35 ter, kapsler, eliksirer, sirupper og lignende, og i overensstemmelse med gængs farmaceutisk praksis. Således
DK 161090B
7 kan de aktive lægemiddelkomponenter til oral indgift i form af tabletter eller kapsler kombineres med en hvilken som helst oral, ikke-toksisk, farmaceutisk acceptabel, inaktiv bærer, såsom lactose, stivelse, saccharose, cel-5 lulose, magnesiumstearat, dicalciumphosphat, calciumsulfat, mannitol og lignende; til oral indgift i flydende form kan de aktive lægemiddelkomponenter kombineres med en hvilken som helst oral, ikke-toksisk farmaceutisk acceptabel, inaktiv bærer, såsom ethanol og lignende.
10 Desuden kan, når det er ønsket eller nødvendigt, egnede bindemidler, smøremidler, disintegreringsmidler og farvestoffer også inkorporeres i blandingen. Egnede bindemidler omfatter stivelse, gelatine, naturlige sukkerforbindelser, majssødemidler, naturlige og syntetiske gum-15 misorter, såsom akacie, natriumalginat, carboxymethylcel-lulose, polyethylenglycol og vokstyper. Smøremidler, der kan anvendes i disse doseringsformer, omfatter borsyre, natriumbenzoat, natriumacetat, natriumchlorid og lignende. Disintegreringsmidler omfatter bl.a. stivelse, methylcel-20 lulose, agar, bentonit, guargummi og lignende.
Forbindelserne ifølge opfindelsen udviser an-tihypertensiv aktivitet, hvilket er bestemt ved prøven på ikke-anæstetiserede, spontant hypertensive rotter (SHR) og udviser calciumion-antagonisme som påvist i 25 isolerede segmenter fra thorax aorta fra spontant hypertensive hanrotter.
De prøvemetoder, der anvendes til at måle den antihypertensive antivitet og calcium-antagonistaktivi-teten hos forbindelser ifølge opfindelsen, er beskrevet 30 nedenfor.
Anti-hypertensiv aktivitet
Ikke-anæstetiserede, spontant hypertensive hanrotter, 11-16 uger gamle, anvendes til denne prøvemetode.
De forbindelser, der skal afprøves, indgives intraga-35
DK 161090 B
8 o strisk i en dosis på 50 mg/kg eller intraarterielt/in-travenøst i en dosis på 10 mg/kg.
Det gennemsnitlige begyndelsesarterieblodtryk måles direkte via et i forvejen indopereret arterieka-5 teter umiddelbart før indgift af prøveforbindelsen. Der foretages blodtrykaflæsninger 1, 2, 3 og 4 timer efter indgift af prøveforbindelsen. En forbindelse bedømmes som aktiv, hvis det gennemsnitlige blodtryk efter behandling hos rotter er signifikant afvigende (p mindre end 10 eller lig med 0,05) fra en kontrolgruppes, der sideløbende indgives placebo. Der foretages statistiske sammenligninger ved hjælp parvis Student's t-prøve med tosidige sandsynlighedsberegninger.
Den spontant hypertensive rotte udviser en 15 genetisk-bundet hypertension, der i de fleste henseender ligner væsentlig hypertension hos mennesker. "Gua-nethidin", "Hydralazin", "Methyldopa", "Clonidin-hydro-chlorid" og "Captopril” er aktive ved den ovennævnte hypertensive rotteprøve og er klinisk anvendelige anti-20 hypertensive midler.
Calciumantagonisme i vaskulær glat muskulatur
Isolerede thorax-aorta-segmenter fra spontant hypertensive hanrotter benyttes til denne prøvemetode.
Det udskårne aorta-segment monteres i et vævs-25 bad, der indeholder modificeret Krebs-opløsning. Efter depolarisation af vævet med kalium (100 mmolær) injiceres -3 calcium i kumulative koncentrationer på 1 x 10 molær, -3 -2 3,2 x 10 mc-dsr og 1 x 10 molær i badet, så at der fremkaldes kontraktion af den vaskulære glat-30 te muskulatur. Den udviklede spænding (i gram) måles, og der opnås kontrol-dosisreaktionsværdier. Efter en times inkubation med en prøveforbindelse ved en kon-centration på 1 x 10 molær, gentages samme doser calciumioner. Kontrollens logaritmiske dosis-reaktions-35 kurver og efter behandling analyseres ved lineær regression. pA2~værdien beregnes som et mål for prøve- 9
DK 161090 B
O
forbindelsens calciumantagonisme, jfr. J.M. Van Rossum,
Arch. Int. Pharmacodyn 143, 299-330 (1963). En forbindelse anses for at være aktiv som vaskulær calcium-antagoniét, hvis pA2 er 6,0 eller derover.
5 Calciumioner spiller en væsentlig rolle ved fremkaldelse og vedligeholdelse af kontraktilitet hos vaskulær glat muskulatur. Hos med kalium depolariseret vaskulær glat muskulatur kan calcium-antagonister blokere for calciumioners indtrængen i cellen eller funge-10 re ved en anden mekanisme til inhibering af kontraktioner fremkaldt af calciumioner. Inhiberingen af ved calciumion fremkaldt kontraktion af vaskulær glat muskulatur anvendes til at afprøve forbindelser for vaskulær calcium-antagonisme. Cardiovaskulære sygdomme, såsom 15 arrhythmier, angina-pectoris, hypertension og perifere karsygdomme kan årsagsmæssigt relateres til unormali-teter i den cellulære behandling af calciumioner. Cal-cium-antagonister/indtrængen-blokeringsmidler har vist sig at være af værdi ved behandling af de ovennævnte 20 cardiovaskulære sygdomme eller tilstande. "Verapamil", "Nifedipin", "Diltiazem" og andre lægemidler er aktive ved den ovennævnte prøve og har ligeledes vist sig at være klinisk anvendelige cardiovaskulære midler.
Forbindelserne ifølge opfindelsen er antihy-25 pertensive midler, som med held har vist sig ikke at give tachycardi eller tachyphylakse i prøvedoser, og at sådanne negative bivirkninger undgås eller minimeres, er klart afgørende med hensyn til de foreliggende forbindelsers endelige anvendelighed som cardiova-30 skulære midler
En reduktion af arterieblodtyk sker ved at nedsætte den samlede perifere modstand som følge af kardilatering i arterioler fremkaldt af calciumioners antagonisme i arteriolerne. Nogle af de foretrukne 35 forbindelser ifølge opfindelsen blokerer også optagelsen af calciumioner i dyrkede vaskulære glatmuskel-
DK 161090 B
O
1Q
celler og modarbejder nitrendipins binding til calcium-receptoren i hjertemembranerne.
Opfindelsen vil i det følgende bliye nærmere belyst med hensyn til fremstillingen af forbindelserne 5 ifølge opfindelsen. Fagmænd vil umiddelbart indse, at kendte variationer af betingelserne og fremgangsmåderne i de følgende fremstillingsmetoder kan anvendes til fremstilling af disse forbindelser.
10 Eksempel 1
Diethyl-[[4-[[4-(2-methoxyphenyl)-1-pjperazinyl]methyl]-phenyl]methyl]phosphonat-monohydrochlorid (SC 42352) is {3- O'-™2 OCH- 0X^CH3 .HCl A.
20 ch3-<(0)-ch2ci + p(oc2h5)3-—-> V- tOC2H5> 2
En blanding af 104 g (0f74 mol) α-chlor-p-xylen og 123 g(0,7* mol) triethylphosphit opvarmes i et oliebad til ca»170°C, ved hvilken temperatur tilbagesvaling 30 påbegyndes. Derpå opvarmes fra 170 til 220°C i 2 timer og afkøles til stuetemperatur. Efter destillation giver reaktionsblandingen 126,13 g (70%) klar væske.
35
DK 161090 B
11 o B.
CS3-(Q^-CH2i(OC2H5)2 gif-·» 5
BrCHj-^^-CH^ lOC2H5> 2
En blanding af 22,5 g (0,093 mol) af phospho-10 natesteren fra trin A, 19,8 g (0,111 mol) N-brom-succin-imid og 50 mg benzoylperoxid i 225 ml CC14 opvarmes med en sollampe, indtil opløsningen begynder at tilbagesvale. Opvarmningen fortsættes nogle få minutter, indtil tilbagesvalingen aftager. Reaktionsblandingen opvarmes der-15 på ved tilbagesvaling i 15 minutter, afkøles til stuetemperatur, filtreres og inddampes til tørhed. Den opnåede olie opløses i ether/"Skelly B", vaskes med saltvandsopløsning og tørres over MgSO^. Fjernelse af opløsningsmidlet giver 29,8 g gul olie.
20 C. _ - ^ _/~H + BrCH2"{Q)-CH2P-(OC2H5)2-> °CH3 .2HC1 °ch3
En blanding af 2,5 g (0,013 mol) 1-(o-methoxy-30 phenyl)-piperazin, 4,2 g (0,013 mol) af phosphonatesteren fra trin B og 1,8 g (0,013 mol) pulveriseret i 20 ml DMF omrøres natten over ved stuetemperatur.
Reaktionsblandingen fortyndes med vand og eks-traheres 3 gange med ether. De kombinerede etherlag va-35 skes 2 gange med vand, en gang med 1% NaOH og 2 gange med vand og tørres over MgSO^. Fjernelse af opløsnings-
O
12
DK 161090 B
midlet giver 4,7 g gul olie. Efter chromatografisk rensning og omdannelse til hydrochloridsaltet fås det i overskriften nævnte produkt. Smeltepunkt 146-148°C (dekomp.) Analyse: Beregnet for C23H33N2°4P (HCl-sa3-t) : 5 C 54,59/ H 6,72, N 5,54.
Fundet: C 54,56, H 6,74, N 5,57.
Eksempel 2
Diethyl-[[4-[[4-(2-methylphenyl)-1-piperazinyl]methyl]~ 10 phenyl]methyllphopshophonat-monohydrochlorid (SC 42977) “3 VA/t0 O—.
15 *HC1 \ «3
\ DMF
20 CH3 .2HC1 ch2-^0)- CH3 25
En blanding af 3,24 g (0,013 mol) o-tolyl-pi-perazin.2HCl, 4,2 g (0,013 mol) af den ifølge eksempel IB fremstillede phosphonatester og 5,4 g (0,039 mol) pulveriseret I^CO^ -*· 30 ml DMF omrøres ved stuetempe-30 ratur natten over.
ReaRtionsblandingen fortyndes med vand og ekstraheres 3 gange med ether. De kombinerede organiske lag vaskes 1 gang med vand, 1 gang med 1% NaOH og 1 gang med vand og tørres over MgSO^. Fjernelse af 35 opløsningsmidlet giver 5,2 g gul olie. Efter chromatografisk rensning og omdannelse til hydrochloridsal-
O
13
DK 161090 B
tet fås det i overskriften nævnte produkt som et hvidt faststof. Smeltepunkt 171-172°C (dekomp.).
Analyse: Beregnet for C^H^l^OgP (HC1 salt) : C 60,99, H 7,57, N 6,18, Cl 7,82.
5 Fundet: C 60,47, H 7,17, N 6,43, Cl 7,77.
Ved hjælp af reaktionsskemaerne I, II eller III og de rigtige udgangsmaterialer og betingelser som er eksemplificeret i de særlige metoder, der er forkla-10 ret i eksemplerne 1 og 2, fremstilles de nedenfor i tabel I anførte forbindelser.
Tabel I
Eks. nr._Beregnet Fundet Smp. °C
15 3.
Diethyl-[[4-[[4-(4-methoxyphenyl)--1-piperazinyl]methyl]phenyl]methyl] phosphonat-monohvdrochlorid (SC 42403) 20 --- - •HCl .H20 ^3 25 C 58,91 C 59,01 188- H 7,31 H 7,17 188,5 N 5,97 N 6,00 (dekomp.)
Cl 7,56 Cl 7,51 30 35
O
DK 161090E
14
Tabel I (forts.)
Eks. nr._Beregnet Fundet Smp. °C
4
Diethyl-[[4-[[4-(4-chlorphenyl)-5 1-piperaz iny1]methyl]phenylJ me thyl ]phosphonat-monohydrochlorid (SC 42870) C 55,82 C 55,67 210-211 H 6,60 H 6,50 (dekomp.) 10 N 5,92 N 5,88
Cl 14,98 Cl 15,12 “OO-v^ ° _ ¥ I Η Γ~ ch, 15 HCl KsKat0 æ3 5
Diethyl-[(4-[(4-phenyl-1-pipera-20 zinyl)methyl]phenyl]methyl]phosphonat-monohydrochlor id TSC 42888) C 60,20 C 60,09 197-198 H 7,35 H 7,39 (dekomp.) N 6,38 N 6,42 25 Cl 8,08 Cl 8,02 0^3 ΎΧ8 •HC1 ®3 35
Tabel I (forts.)
Eks. nr._Beregnet Fundet Smp. °C
6 15
DK 161090 B
O
Diethyl-[[4-[[4-(2-chlorphenyl)-5 1-piperazinyl]methyl]phenyl]methyl]- phosphonat-monohydrochlorid (SC 43010) C 55,82 C 55,40 152-153 H 6,60 H 6,39 (dekomp.) N 5,92 N 5,96 10 Cl 14,98 Cl 14,41 Q” r' C1 \U |^> 15 .HCl \(>^\ 7
Diethyl-[[2-[[4-(2-methoxyphenyl)-1-piperaz iny1]methyl]phenyl]me-20 thyl]phosphonat-monohydrochlorid (SC 43089) C 56,12 C 56,40 67-75 H 7,45 H 6,90 N 5,75 N 5,84 25 Cl 7,28 Cl 7,69 5
W>=TS
S*. O
.HCl .H20 35
Tabel I (forts,)
Eks. nr._Beregnet Fundet Snip. °C
8
DK 161090 B
16
O
Diethyl-[[4-[1-[4-(2-methoxyphen-5 yl)-1-piperazinyl]ethyl]phenyl]-methyl]phosphonat-hydrochlorid (2:3) (SC 43098) C 57,51 C 57,62 60-70}fa-H 7,34 H 7,10 seskift til 10 N 5,59 N 5,80 viskos olie
Cl 10,61 Cl 9,18 . r».
” f klcV
®3 . . + 1, .5 HC1 20 9
Diethyl-[[4-[[4-(3-methylphenyl)-1-piperazinyl]methyl]phenyl]methyl]-phosphonat-monohydrochlorid TSC 43137) C 60,99 C 60,76 187-188 25 H 7,57 H 7,43 (dekomp.) N 6,18 N 5,84 Cl 7,83 Cl 8,10 CH3 •HC1 0-y CH3 35
Tabel I (forts.)
Eks. nr._Fundet Beregnet Snip. C
10 17
DK 161090 B
O
Diethyl-[4-[[4-(2-methoxyphenyl)-5 1-piperazinyl]methyl]phenyl]phos- phonat-dihydrochlorid (SC 43250) C 53,77 C 54,03 144-148 H 6,77 H 6,61 (dekomp.) N 5,70 N 5,90 10 Cl 14,43 Cl 13,37 \_/^ W ,2HC1
/ Nr XH3 0 J
CH3^ 11 20 Diethyl-[[4—[[4-(2-methoxyphenyl)- 1-piperazinyl]carbonyl]phenyl]methyl]-phosphonat-sulfat (SC 43431) C 44,00 C 44,298 176-186 H 5,57 H 5,60 (dekomp.) 25 N 4,46 N 4,44
Cl 9,45 Cl 9,87
. O
30 J I^JL
οχ Η, + 1,85 H .SO 2 4 35
Tabel I (forts.)
Eks. nr._Beregnet Fundet Smp. °C
12
O
DK 161090 B
18
Diethyl-[[4-[[4-(2,6-dimethylphen-5 yl)-1-piperazinyl]methyl]phenyl]-methyl]-phopshonat-monohydrochlorid (SC 43546) C 61,72 C 61,94 176-179 H 7,55 H 7,77 10 N 6,00 N 6,29
Μ_/-λ /U
\h\_j ·3 CH3 .HCl 13
Diethyl- [-1- [4- [ [4- (2-methoxyphe_nyl) -20 1-piperazinyl]methyl]phenyl]ethyl]-phopshonat-hydrochlorid, (2:3) TSC 43677) C 56,58 C 56,92 119-126 H 7,27 H 7,11 (dekomp.) 25 N 5,50 N 5,54
Cl 10,44 Cl 10,65 . QO-χv/' / I V\ H3C 1 ch3 ®3 .
35
O
19
DK 161090 B
De resultater, der iagttages med hensyn til visse af de foretrukne forbindelser ifølge opfindelsen ved ikke-anæstetiserede, spontant hypertensive rotteprøven (SHR), der tidligere er beskrevet, er anført i 5 tabel II nedenfor.
Tabel II
Forbindelse SHR (-mm Hg} efter 4 timer.
Eks. nr._10 mg/kg intravenøst_ 10 1 -92,5 2 -89,8 3 -40,3 5 -44,0 6 -43,0 15 7 -40,4 9 -28,8 10 -58,9 12 -25,9 13 -76,3 20
Calciumion-antagonistaktiviteterne (pA2“-vær-dier) for forbindelserne ifølge eksemplerne 1, 10, 12 og 13 er hhv. 6,5, 6,6, 6,8 og 6,9 målt i overensstemmelse med den tidligere beskrevne prøve.
25 Selv om opfindelsen er blevet beskrevet og be lyst under henvisning til visse foretrukne udførelsesformer, vil fagfolk indse, at der kan foretages forskellige ændringer, modifikationer og substitutioner, uden at man derved afviger fra opfindelsens idé. Således 30 kan der anvendes andre effektive doseringer end de ovenfor anførte foretrukne intervaller som følge af variationer i det behandlede pattedyrs reaktion, hypertensionens sværhedsgrad, eventuelle iagttagne negative virkninger, der har relation til doseringen, og lignende be-35 tragtninger. Ligeledes kan de særlige farmakologiske reaktioner, der iagttages, variere afhængigt af de . sær-
O
DK 161090 B
20 lige aktive forbindelser, der er valgt, eller af om forskellige aktive forbindelser anvendes kombineret med eller i nærvær af egnede farmaceutiske bærere, samt af den anvendte tilberedningstype og indgiftsvej.
5 10 15 20 25 30 35
DK 161090 B
21
Patentkrav .
1. phenylpiperazinphosphonater, kendetegnet ved, at de har den almene formel 5
X
"VTA ΛΛ /7^-1“;%'! „ -'-w
Y
i hvilken X, Y og W er ens eller forskellige og hver er valgt blandt 15 hydrogen, C1_4-alkoxy, C1_6-alkyl og halogen, CHo i A er -CH2“ eller -CH-, og 20 CHo Z er en binding eller -CH2- eller -CH-, samt farmaceutisk acceptable syreadditionssalte heraf.
2. Forbindelse ifølge krav 1, kendeteg-25 net ved, at to af symbolerne X, Y og W er hydrogen, og det andet er C1_4~alkoxy eller C^g-alkyl.
3. Forbindelse ifølge krav 1, kendetegnet ved, at A er -CH2-. .
4. Forbindelse ifølge krav 1, kendeteg- 30 CH^ net ved, at Z er -CH2- eller -CH-.
5. Forbindelse ifølge krav 1, kendetegnet ved, at Z er -CH2“.
6. Forbindelse ifølge krav 1, kendeteg-35 net ved, at den har formlen
DK 161090 B
22 g (O) _^~CH2~\Oy-CH2~P“OCH2CH3 \ ' OCH,CH, 0CH3 7. Forbindelse ifølge krav 1, kendetegnet ved, at den har formlen \ - o-ch2ch3 CH3 15 8. Forbindelse ifølge krav 1, kende tegnet ved, at den har formlen
^^ pTT O
(CN^^-ch2-^0)-® ~|-°CH2CH3 20 \ 0-CH2CH3 OCH3 9. Farmaceutisk sammensætning, kendetegnet ved, at den omfatter en farmaceutisk bæ-25 rer kombineret med en forbindelse ifølge krav 1.
10. Sammensætning ifølge krav 9, kendetegnet ved, at forbindelsen har formlen 30 ©“"w"CB2-^-CH2-(-OCH2®3 \ 0-CH2CH3 och3 35
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76023085A | 1985-07-29 | 1985-07-29 | |
US76023085 | 1985-07-29 | ||
US06/880,560 US4704382A (en) | 1985-07-29 | 1986-07-08 | Phenylpiperazine phosphonates |
US88056086 | 1986-07-08 |
Publications (4)
Publication Number | Publication Date |
---|---|
DK355686D0 DK355686D0 (da) | 1986-07-25 |
DK355686A DK355686A (da) | 1987-01-30 |
DK161090B true DK161090B (da) | 1991-05-27 |
DK161090C DK161090C (da) | 1991-11-18 |
Family
ID=27116794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK355686A DK161090C (da) | 1985-07-29 | 1986-07-25 | Phenylpiperazinphosphonater samt farmaceutisk sammensaetning indeholdende disse |
Country Status (13)
Country | Link |
---|---|
US (1) | US4704382A (da) |
EP (1) | EP0211346B1 (da) |
AU (1) | AU595220B2 (da) |
CA (1) | CA1275412C (da) |
DE (1) | DE3665589D1 (da) |
DK (1) | DK161090C (da) |
FI (1) | FI82834C (da) |
GR (1) | GR861958B (da) |
IL (1) | IL79525A (da) |
NO (1) | NO863037L (da) |
NZ (1) | NZ216971A (da) |
PH (1) | PH23037A (da) |
PT (1) | PT83078B (da) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0651625B2 (ja) * | 1986-12-29 | 1994-07-06 | 株式会社大塚製薬工場 | 高脂質血症治療剤 |
CA1321751C (en) * | 1989-02-21 | 1993-08-31 | Eugene C. Crichlow | Mechanism mediating ruminal stasis in ruminal lactic acidosis |
IL158941A0 (en) * | 2001-05-22 | 2004-05-12 | Neurogen Corp | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
EP1935885A3 (en) * | 2001-05-22 | 2008-10-15 | Neurogen Corporation | Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues. |
EP2147679B1 (en) | 2001-07-25 | 2014-06-25 | Raptor Pharmaceutical, Inc. | Compositions for blood-brain barrier transport |
US7459461B2 (en) * | 2001-10-19 | 2008-12-02 | Ortho-Mcneil Pharmaceutical, Inc. | Phosphonic acid compounds as inhibitors of serine proteases |
TW200536525A (en) * | 2004-03-31 | 2005-11-16 | Suntory Ltd | Adiponectin enhancer |
WO2005110982A2 (en) * | 2004-04-07 | 2005-11-24 | Neurogen Corporation | Substituted 1-benzyl-4-substituted piperazine analogues |
WO2005110989A1 (en) * | 2004-04-07 | 2005-11-24 | Neurogen Corporation | Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues |
TW200609219A (en) * | 2004-06-17 | 2006-03-16 | Neurogen Corp | Aryl-substituted piperazine derivatives |
DK1889198T3 (da) | 2005-04-28 | 2015-02-09 | Proteus Digital Health Inc | Farma-informatiksystem |
WO2008036682A2 (en) | 2006-09-18 | 2008-03-27 | Raptor Pharmaceutical Inc. | Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates |
DK2398500T3 (da) | 2009-02-20 | 2019-05-13 | 2 Bbb Medicines B V | Glutathion-baseret lægemiddelafgivelsessystem |
IL255113B (en) | 2009-05-06 | 2022-09-01 | Laboratory Skin Care Inc | Preparations for administration through the skin that include complexes of an active substance with calcium phosphate and methods of using them |
US20120077778A1 (en) | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
WO2022057858A1 (zh) * | 2020-09-17 | 2022-03-24 | 浙江海正药业股份有限公司 | 酰胺膦氧类衍生物及其制备方法和用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3804836A (en) * | 1972-05-26 | 1974-04-16 | Hoechst Co American | N-phenyl-n'-dialkylphosphinylalkyl-piperazines |
DE3139970A1 (de) * | 1981-10-08 | 1983-04-28 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
-
1986
- 1986-07-08 US US06/880,560 patent/US4704382A/en not_active Expired - Fee Related
- 1986-07-24 CA CA000514618A patent/CA1275412C/en not_active Expired - Lifetime
- 1986-07-25 NZ NZ216971A patent/NZ216971A/xx unknown
- 1986-07-25 IL IL79525A patent/IL79525A/xx unknown
- 1986-07-25 GR GR861958A patent/GR861958B/el unknown
- 1986-07-25 DE DE8686110244T patent/DE3665589D1/de not_active Expired
- 1986-07-25 DK DK355686A patent/DK161090C/da not_active IP Right Cessation
- 1986-07-25 FI FI863064A patent/FI82834C/fi not_active IP Right Cessation
- 1986-07-25 AU AU60555/86A patent/AU595220B2/en not_active Ceased
- 1986-07-25 PH PH34066A patent/PH23037A/en unknown
- 1986-07-25 EP EP86110244A patent/EP0211346B1/en not_active Expired
- 1986-07-28 NO NO863037A patent/NO863037L/no unknown
- 1986-07-28 PT PT83078A patent/PT83078B/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NZ216971A (en) | 1989-05-29 |
GR861958B (en) | 1986-12-22 |
FI82834C (fi) | 1991-04-25 |
FI82834B (fi) | 1991-01-15 |
DK355686D0 (da) | 1986-07-25 |
NO863037D0 (no) | 1986-07-28 |
EP0211346B1 (en) | 1989-09-13 |
AU6055586A (en) | 1987-02-05 |
PT83078B (pt) | 1988-07-01 |
DK161090C (da) | 1991-11-18 |
IL79525A (en) | 1990-06-10 |
DK355686A (da) | 1987-01-30 |
EP0211346A3 (en) | 1987-05-27 |
FI863064A (fi) | 1987-01-30 |
FI863064A0 (fi) | 1986-07-25 |
DE3665589D1 (en) | 1989-10-19 |
IL79525A0 (en) | 1986-10-31 |
CA1275412C (en) | 1990-10-23 |
PH23037A (en) | 1989-03-10 |
NO863037L (no) | 1987-01-30 |
US4704382A (en) | 1987-11-03 |
AU595220B2 (en) | 1990-03-29 |
PT83078A (en) | 1986-08-01 |
EP0211346A2 (en) | 1987-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK161090B (da) | Phenylpiperazinphosphonater samt farmaceutisk sammensaetning indeholdende disse | |
FI78470B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara dihydropyridinderivat. | |
CZ281209B6 (cs) | Deriváty indolizinu, způsob jejich přípravy a farmaceutická nebo veterinární kompozice je obsahující | |
US4059621A (en) | Substituted benzamido propanolamines | |
US4593042A (en) | Bicyclo-substituted phenylacetonitrile derivatives | |
PL116420B1 (en) | Process for preparing novel phthalazine derivatives | |
JPS6364428B2 (da) | ||
US3354174A (en) | 1-and 2-benzimidazolyl-lower-alkylamidoximes, amidines-, and guanidines | |
HU185088B (en) | Process for preparing 1,3-dihydeo-6-methyl-7-hydroxy-furo/3,4-c-/-pyridine derivatives | |
EA016726B1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
IE840826L (en) | Furo-pyridines | |
FI80262B (fi) | Foerfarande foer framstaellning av saosom antiiskemiska och antihypertensiva medel anvaendbara 1,4-dihydropyridinderivat. | |
IE51179B1 (en) | Pyridoxine derivatives,process for preparing them and use in therapeutics | |
DK159114B (da) | Benzyldihydrofuropyridinderivater og praeparater indeholdende disse forbindelser | |
GB2054566A (en) | 1-aryl-4-arylsulphonyl-3-aminopropoxy-1h-pyrazoles medicaments containing them and processes for their preparation | |
HU191895B (en) | Process for producing 2-guanidino-4-imidazolyl-thiazoles | |
US4551534A (en) | Aralkyl or aryloxyalkyl 1,7-naphthyridine-3-carboxylic acid esters | |
NZ205700A (en) | 1-(4-(omega-(3-aryl-1-oxo-2,3-dihydro-1h-isoindol-2-yl)alkyl)benzenesulphonyl)-3-substituted ureas | |
JPS61282359A (ja) | N−ベンジル−ピペリジン化合物およびそれを含有する医薬組成物 | |
EP0183216A1 (en) | N-(Aralkoxybenzyl)-4(benzhydryl) piperidines | |
DK162999B (da) | Imidazoquinazolinforbindelse samt fremgangsmaade til fremstilling deraf | |
US20080090885A1 (en) | Preparation of losartan 5-carboxylic acid and use thereof | |
DK158000B (da) | Analogifremgangsmaade til fremstilling af 3-(substitueret benzoyl)-indolizinderivater | |
FI82249C (fi) | Foerfarande foer framstaellning av nya pyridinderivat. | |
FI56378C (fi) | Foerfarande foer framstaellning av terapeutiskt aktiva 1-(4-bromfenyl)-1-pyridyl-3-dimetylamino-prop-1-enderivat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUP | Patent expired |